Annual EBIT
-$69.47 M
+$29.60 M+29.88%
31 December 2023
Summary:
EyePoint Pharmaceuticals annual earnings before interest & taxes is currently -$69.47 million, with the most recent change of +$29.60 million (+29.88%) on 31 December 2023. During the last 3 years, it has fallen by -$31.33 million (-82.15%). EYPT annual EBIT is now -864.11% below its all-time high of $12.42 million.EYPT EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBIT
-$29.36 M
+$1.47 M+4.75%
30 September 2024
Summary:
EyePoint Pharmaceuticals quarterly earnings before interest & taxes is currently -$29.36 million, with the most recent change of +$1.47 million (+4.75%) on 30 September 2024. Over the past year, it has dropped by -$16.75 million (-132.80%). EYPT quarterly EBIT is now -241.23% below its all-time high of $20.79 million, reached on 30 September 2014.EYPT Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBIT
-$103.49 M
-$16.75 M-19.31%
30 September 2024
Summary:
EyePoint Pharmaceuticals TTM earnings before interest & taxes is currently -$103.49 million, with the most recent change of -$16.75 million (-19.31%) on 30 September 2024. Over the past year, it has dropped by -$5.37 million (-5.47%). EYPT TTM EBIT is now -1046.04% below its all-time high of $10.94 million, reached on 30 September 2014.EYPT TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
EYPT EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +29.9% | -132.8% | -5.5% |
| 3 y3 years | -82.2% | -91.8% | -113.3% |
| 5 y5 years | -61.3% | -111.6% | -146.4% |
EYPT EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -82.2% | +29.9% | -132.8% | +31.2% | -113.3% | at low |
| 5 y | 5 years | -82.2% | +29.9% | -1400.3% | +31.2% | -212.0% | at low |
| alltime | all time | -864.1% | +29.9% | -241.2% | +47.4% | -1046.0% | at low |
EyePoint Pharmaceuticals EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$29.36 M(-4.8%) | -$103.49 M(+19.3%) |
| June 2024 | - | -$30.83 M(+5.3%) | -$86.74 M(+10.6%) |
| Mar 2024 | - | -$29.28 M(+108.9%) | -$78.40 M(+12.9%) |
| Dec 2023 | -$69.47 M(-29.9%) | -$14.02 M(+11.1%) | -$69.47 M(-29.2%) |
| Sept 2023 | - | -$12.61 M(-43.9%) | -$98.12 M(-5.0%) |
| June 2023 | - | -$22.48 M(+10.5%) | -$103.27 M(+3.6%) |
| Mar 2023 | - | -$20.35 M(-52.3%) | -$99.64 M(+0.6%) |
| Dec 2022 | -$99.06 M(+87.2%) | -$42.67 M(+140.3%) | -$99.06 M(+33.1%) |
| Sept 2022 | - | -$17.76 M(-5.8%) | -$74.44 M(+3.4%) |
| June 2022 | - | -$18.85 M(-4.7%) | -$71.99 M(+16.5%) |
| Mar 2022 | - | -$19.78 M(+9.6%) | -$61.77 M(+16.7%) |
| Dec 2021 | -$52.92 M(+38.8%) | -$18.04 M(+17.9%) | -$52.92 M(+9.1%) |
| Sept 2021 | - | -$15.31 M(+77.3%) | -$48.52 M(+38.0%) |
| June 2021 | - | -$8.63 M(-21.0%) | -$35.17 M(-6.7%) |
| Mar 2021 | - | -$10.93 M(-19.9%) | -$37.68 M(-1.3%) |
| Dec 2020 | -$38.14 M(-24.7%) | -$13.64 M(+597.1%) | -$38.19 M(+15.1%) |
| Sept 2020 | - | -$1.96 M(-82.4%) | -$33.17 M(-26.4%) |
| June 2020 | - | -$11.14 M(-2.6%) | -$45.09 M(+2.8%) |
| Mar 2020 | - | -$11.44 M(+32.7%) | -$43.84 M(-13.4%) |
| Dec 2019 | -$50.62 M(+17.5%) | -$8.62 M(-37.9%) | -$50.62 M(+20.5%) |
| Sept 2019 | - | -$13.88 M(+40.2%) | -$41.99 M(-30.5%) |
| June 2019 | - | -$9.90 M(-45.7%) | -$60.43 M(-30.1%) |
| Mar 2019 | - | -$18.22 M(-43.6%) | -$86.49 M(+9.8%) |
| Dec 2018 | -$43.08 M(-17.9%) | - | - |
| Sept 2018 | - | -$32.31 M(-10.1%) | -$78.76 M(+50.2%) |
| June 2018 | -$52.45 M(+183.7%) | -$35.96 M(+668.7%) | -$52.43 M(+132.9%) |
| Mar 2018 | - | -$4.68 M(-19.5%) | -$22.51 M(-2.1%) |
| Dec 2017 | - | -$5.81 M(-2.9%) | -$23.00 M(+33.1%) |
| Sept 2017 | - | -$5.98 M(-1.0%) | -$17.28 M(-6.5%) |
| June 2017 | -$18.48 M(-14.8%) | -$6.04 M(+17.2%) | -$18.48 M(-1.8%) |
| Mar 2017 | - | -$5.16 M(+5389.4%) | -$18.82 M(+0.3%) |
| Dec 2016 | - | -$94.00 K(-98.7%) | -$18.76 M(-21.5%) |
| Sept 2016 | - | -$7.19 M(+12.6%) | -$23.90 M(+10.1%) |
| June 2016 | -$21.70 M(-438.0%) | -$6.38 M(+25.3%) | -$21.70 M(+5.8%) |
| Mar 2016 | - | -$5.10 M(-2.7%) | -$20.52 M(+0.2%) |
| Dec 2015 | - | -$5.24 M(+5.1%) | -$20.47 M(+5.8%) |
| Sept 2015 | - | -$4.98 M(-4.2%) | -$19.35 M(-401.4%) |
| June 2015 | $6.42 M(-147.3%) | -$5.20 M(+2.9%) | $6.42 M(-15.6%) |
| Mar 2015 | - | -$5.05 M(+22.7%) | $7.61 M(-27.1%) |
| Dec 2014 | - | -$4.12 M(-119.8%) | $10.44 M(-4.6%) |
| Sept 2014 | - | $20.79 M(-617.9%) | $10.94 M(-180.6%) |
| June 2014 | -$13.57 M(+12.8%) | -$4.01 M(+80.6%) | -$13.57 M(+0.1%) |
| Mar 2014 | - | -$2.22 M(-38.5%) | -$13.55 M(-4.1%) |
| Dec 2013 | - | -$3.61 M(-2.8%) | -$14.13 M(+7.4%) |
| Sept 2013 | - | -$3.72 M(-6.9%) | -$13.17 M(+9.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2013 | -$12.03 M(-51.9%) | -$4.00 M(+42.2%) | -$12.03 M(-51.8%) |
| Mar 2013 | - | -$2.81 M(+6.2%) | -$24.97 M(+0.3%) |
| Dec 2012 | - | -$2.64 M(+2.4%) | -$24.89 M(-37.4%) |
| Sept 2012 | - | -$2.58 M(-84.7%) | -$39.75 M(+0.1%) |
| June 2012 | -$25.00 M(+183.1%) | -$16.93 M(+520.9%) | -$39.69 M(+81.3%) |
| Mar 2012 | - | -$2.73 M(-84.4%) | -$21.90 M(-1.8%) |
| Dec 2011 | - | -$17.50 M(+591.6%) | -$22.31 M(+181.4%) |
| Sept 2011 | - | -$2.53 M(-393.6%) | -$7.93 M(-10.2%) |
| June 2011 | -$8.83 M(-197.2%) | $862.00 K(-127.5%) | -$8.83 M(-456.3%) |
| Mar 2011 | - | -$3.14 M(+0.6%) | $2.48 M(-10.0%) |
| Dec 2010 | - | -$3.12 M(-9.1%) | $2.75 M(-52.2%) |
| Sept 2010 | - | -$3.44 M(-128.2%) | $5.76 M(-36.6%) |
| June 2010 | $9.09 M(-362.6%) | $12.17 M(-525.2%) | $9.09 M(-562.9%) |
| Mar 2010 | - | -$2.86 M(+2433.6%) | -$1.96 M(-1764.4%) |
| Dec 2009 | - | -$113.00 K(+5.6%) | $118.00 K(-109.9%) |
| Sept 2009 | - | -$107.00 K(-109.6%) | -$1.19 M(-65.6%) |
| June 2009 | -$3.46 M(-95.4%) | $1.12 M(-243.3%) | -$3.46 M(-94.3%) |
| Mar 2009 | - | -$781.00 K(-45.0%) | -$60.37 M(-8.8%) |
| Dec 2008 | - | -$1.42 M(-40.3%) | -$66.20 M(-9.1%) |
| Sept 2008 | - | -$2.38 M(-95.7%) | -$72.81 M(-3.7%) |
| June 2008 | -$75.65 M(+112.8%) | -$55.79 M(+744.1%) | -$75.65 M(+32.3%) |
| Mar 2008 | - | -$6.61 M(-17.8%) | -$57.18 M(+13.2%) |
| Dec 2007 | - | -$8.04 M(+54.2%) | -$50.51 M(-0.9%) |
| Sept 2007 | - | -$5.21 M(-86.0%) | -$50.97 M(+13.4%) |
| June 2007 | -$35.54 M(+28.4%) | -$37.32 M(<-9900.0%) | -$44.97 M(+23.6%) |
| Mar 2007 | - | $65.00 K(-100.8%) | -$36.38 M(+0.8%) |
| Dec 2006 | - | -$8.50 M(-1175.4%) | -$36.09 M(+34.1%) |
| Sept 2006 | - | $790.40 K(-102.8%) | -$26.92 M(-1.5%) |
| June 2006 | -$27.68 M(+90.2%) | -$28.73 M(-8264.7%) | -$27.33 M(+100.5%) |
| Mar 2006 | - | $351.90 K(-47.5%) | -$13.63 M(-1.4%) |
| Dec 2005 | - | $670.70 K(+78.8%) | -$13.82 M(-3.6%) |
| Sept 2005 | - | $375.10 K(-102.5%) | -$14.33 M(-1.5%) |
| June 2005 | -$14.55 M(+133.3%) | -$15.03 M(-9470.5%) | -$14.56 M(+143.3%) |
| Mar 2005 | - | $160.40 K(-0.9%) | -$5.98 M(-1.4%) |
| Dec 2004 | - | $161.80 K(+7.4%) | -$6.07 M(-1.5%) |
| Sept 2004 | - | $150.70 K(-102.3%) | -$6.16 M(-1.4%) |
| June 2004 | -$6.24 M(+73.4%) | -$6.46 M(-8954.7%) | -$6.25 M(+81.7%) |
| Mar 2004 | - | $72.90 K(+1.5%) | -$3.44 M(-1.6%) |
| Dec 2003 | - | $71.80 K(+10.6%) | -$3.49 M(-1.6%) |
| Sept 2003 | - | $64.90 K(-101.8%) | -$3.55 M(-1.4%) |
| June 2003 | -$3.60 M(+181.3%) | -$3.65 M(<-9900.0%) | -$3.60 M(-7728.4%) |
| Mar 2003 | - | $16.70 K(+7.7%) | $47.20 K(+54.8%) |
| Dec 2002 | - | $15.50 K(+3.3%) | $30.50 K(+103.3%) |
| Sept 2002 | - | $15.00 K | $15.00 K |
| June 2002 | -$1.28 M(+194.2%) | - | - |
| June 2001 | -$434.60 K | - | - |
FAQ
- What is EyePoint Pharmaceuticals annual earnings before interest & taxes?
- What is the all time high annual EBIT for EyePoint Pharmaceuticals?
- What is EyePoint Pharmaceuticals annual EBIT year-on-year change?
- What is EyePoint Pharmaceuticals quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for EyePoint Pharmaceuticals?
- What is EyePoint Pharmaceuticals quarterly EBIT year-on-year change?
- What is EyePoint Pharmaceuticals TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for EyePoint Pharmaceuticals?
- What is EyePoint Pharmaceuticals TTM EBIT year-on-year change?
What is EyePoint Pharmaceuticals annual earnings before interest & taxes?
The current annual EBIT of EYPT is -$69.47 M
What is the all time high annual EBIT for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals all-time high annual earnings before interest & taxes is $12.42 M
What is EyePoint Pharmaceuticals annual EBIT year-on-year change?
Over the past year, EYPT annual earnings before interest & taxes has changed by +$29.60 M (+29.88%)
What is EyePoint Pharmaceuticals quarterly earnings before interest & taxes?
The current quarterly EBIT of EYPT is -$29.36 M
What is the all time high quarterly EBIT for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals all-time high quarterly earnings before interest & taxes is $20.79 M
What is EyePoint Pharmaceuticals quarterly EBIT year-on-year change?
Over the past year, EYPT quarterly earnings before interest & taxes has changed by -$16.75 M (-132.80%)
What is EyePoint Pharmaceuticals TTM earnings before interest & taxes?
The current TTM EBIT of EYPT is -$103.49 M
What is the all time high TTM EBIT for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals all-time high TTM earnings before interest & taxes is $10.94 M
What is EyePoint Pharmaceuticals TTM EBIT year-on-year change?
Over the past year, EYPT TTM earnings before interest & taxes has changed by -$5.37 M (-5.47%)